Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext ScienceFRA:VV5 55 EV-to-EBITDA is 9.98 as of Aug. 27, 2026, which is 34% above its 10-year median of 7.46. GuruFocus rates FRA:VV5 with a GF Score™ of 55/100 and a GF Value™ of €1.11. The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Vext Science ranks better than 63.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vext Science's enterprise value is €68.04 Mil.
Vext Science's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €6.82 Mil. Therefore, Vext Science's EV-to-EBITDA for today is 9.98.
The historical rank and industry rank for Vext Science's EV-to-EBITDA or its related term are showing as below:
FRA:VV5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.85 Med: 7.46 Max: 52.61
Current: 9.61
During the past 9 years, the highest EV-to-EBITDA of Vext Science was 52.61. The lowest was -32.85. And the median was 7.46.
FRA:VV5's EV-to-EBITDA is ranked better than 63.08% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs FRA:VV5: 9.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vext Science's PE Ratio (TTM) for today is calculated as:
Vext Science's share price for today is €0.17.
Vext Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vext Science's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vext Science's EV-to-EBITDA falls into.
Vext Science's current Enterprise Value is €68.04 Mil.
Vext Science's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a EV-to-EBITDA of 9.98 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vext Science. This is 34% above median its historical median of 7.46. According to the industry distribution chart, Vext Science ranks #271 out of 734 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Vext Science's EV-to-EBITDA too high?
Vext Science's current EV-to-EBITDA of 9.98 is 34% above median its 10-year median of 7.46. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Vext Science's value of 9.98 is 23.4% below this industry median. Based on the distribution chart, Vext Science ranks #271 out of 734 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vext Science has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #271 out of 734 companies for EV-to-EBITDA. This puts Vext Science in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. Vext Science's value of 9.98 is 23.4% below this benchmark. While the company's 10-year median is 7.46 vs. the industry median of 13.03, Vext Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current EV-to-EBITDA of 9.98 is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vext Science. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current EV-to-EBITDA is 9.98, which is 34% above median its own 10-year median of 7.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current EV-to-EBITDA of 9.98. The stock's GF Value™ is €1.11, compared to a current price of €0.17 — trading 84.7% below its estimated fair value. The current EV-to-EBITDA is 9.98, which is 34% above median its 10-year median of 7.46 and 23.4% below the Drug Manufacturers industry median of 13.03. Vext Science's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current EV-to-EBITDA is 9.98 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.17 is trading 84.7% below its estimated GF Value™ of €1.11.
Key valuation signals for FRA:VV5:
EV-to-EBITDA: 9.98 (34% above median its 10-year median of 7.46)
GF Value™: €1.11 vs. price of €0.17 (84.7% below fair value)
Industry Position: 23.4% below the Drug Manufacturers median (#271 of 734)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
55GF Score
Get the complete analysis for FRA:VV5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
